Phase 2a Dose-Rising, Safety, Tolerability, and Efficacy Study of Topical SOR007 for Cervical Intraepithelial Neoplasia (CIN)

Trial Profile

Phase 2a Dose-Rising, Safety, Tolerability, and Efficacy Study of Topical SOR007 for Cervical Intraepithelial Neoplasia (CIN)

Not yet recruiting
Phase of Trial: Phase II

Latest Information Update: 11 May 2017

At a glance

  • Drugs Paclitaxel (Primary)
  • Indications Cervical intraepithelial neoplasia
  • Focus Adverse reactions
  • Sponsors Dfb Soria
  • Most Recent Events

    • 11 May 2017 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top